-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $138

Benzinga·12/09/2025 10:31:31
Listen to the news
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $75 to $138.